Heart Failure POC And LOC Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type (Proteomic testing, Metabolomic testing, Genomic testing), By Technology (Microfluidics, Array-based systems, Others), By End Use (Clinics, Hospitals, Home, Assisted living healthcare facilities, Laboratory, Others), By Region & Competition, 2020-2030F

Market Overview

Global Heart Failure POC And LOC Devices Market was valued at USD 110.24 million in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.25% through 2030. The Global Heart Failure POC and LOC Devices Market refers to a rapidly evolving sector within the healthcare industry that focuses on the development and deployment of innovative diagnostic and monitoring devices specifically designed for heart failure patients. These devices aim to provide more efficient, cost-effective, and patient-friendly solutions for the detection, management, and treatment of heart failure. Also, certain development also leads to the growth of global heart failure LOC and POC devices market. For example, in May 2023, research supported by the British Heart Foundation and the National Institute for Health Research (NIHR) resulted in the development of the CoDe-ACS algorithm. This advanced tool analyzes patient data—such as age, sex, heart metrics, and test results—to accurately assess an individual's risk of a heart attack. Such innovations are poised to enhance the efficiency and adoption of point-of-care (POC) testing, reinforcing its essential role in modern healthcare by enabling earlier and more precise risk assessment.

Lab-on-a-Chip (LOC) technology enables rapid, high-throughput analyses, improving ease of use and reliability in disease diagnosis. Growing R&D investments in LOC-based assays, particularly for cardiovascular diseases (CVD) such as heart failure, are driving market growth. With CVD being a leading cause of mortality worldwide, the increasing need for early detection and effective management is boosting demand for LOC technology in diagnostics. The shift towards decentralized healthcare and personalized medicine is accelerating the adoption of point-of-care (POC) and LOC devices, offering faster, more accessible diagnostic solutions. Government bodies are actively supporting LOC development through funding initiatives and regulatory approvals, encouraging further innovation. Technological advancements, such as miniaturization, microfluidics, and AI integration, are enhancing the accuracy and efficiency of LOC-based diagnostics. These factors collectively contribute to the expanding market for LOC technology, positioning it as a crucial tool in modern healthcare, particularly for the early and efficient diagnosis of CVD and other critical diseases.

Key Market Drivers

Rising Prevalence of Heart Failure

Heart failure is a pervasive and chronic cardiovascular condition, affecting millions of people worldwide. With an aging population, sedentary lifestyles, and an increasing prevalence of risk factors such as obesity and diabetes, the incidence of heart failure is on the rise. However, this health crisis has given rise to an opportunity for innovation in healthcare. The Global Heart Failure Point of Care (POC) and Lab on a Chip (LOC) Devices Market is experiencing remarkable growth due to the escalating prevalence of heart failure.

Diabetes is a global health crisis, placing a substantial burden on developing countries like India, which is often referred to as the diabetes capital of the world. According to the ICMR-INDIAB study, over 101 million people in India are living with diabetes. The disease is linked to high morbidity and mortality, with nearly 46% of diabetic patients developing cardiovascular disease (CVD) during their lifetime. CVD is a leading cause of death among Type 2 diabetes (T2D) patients, accounting for nearly 50% of diabetes-related fatalities.  Approximately 30% of diabetic patients develop heart failure, and those with both T2D and heart failure face an eightfold higher risk of death compared to individuals without heart failure. These alarming statistics highlight the urgent need for early diagnosis, intervention, and innovative treatment strategies to reduce the impact of diabetes-related cardiovascular complications.

Heart failure is a global health epidemic, with a prevalence that continues to climb. According to the American Heart Association, over 6 million adults in the United States alone live with heart failure, and it is projected that this number will further increase in the coming years. The situation is similar in many other countries.

The increasing prevalence of heart failure necessitates more efficient diagnostic tools. POC and LOC devices are designed to provide rapid and accurate diagnostics, allowing healthcare professionals to identify heart failure quickly and accurately. With the demand for early diagnosis and intervention, these devices have a pivotal role to play.

Once diagnosed, heart failure patients require ongoing management to maintain their health and prevent complications. POC and LOC devices are not limited to diagnosis; they also offer convenient and timely monitoring solutions. These devices empower both healthcare providers and patients to manage the condition effectively.

Heart failure is associated with significant healthcare costs, including hospitalizations and emergency room visits. POC and LOC devices offer a cost-effective alternative by reducing the need for these costly interventions. Early detection and management can prevent complications and lower healthcare expenditure.

Modern healthcare is increasingly adopting a patient-centric approach. POC and LOC devices fit seamlessly into this model by enabling patients to take a more active role in their health management. With real-time data at their fingertips, patients can make informed decisions and communicate effectively with their healthcare providers.

The rise of telemedicine and remote healthcare monitoring has been further accelerated by the COVID-19 pandemic. POC and LOC devices are integral to this trend. They enable remote monitoring of patients, reducing the need for in-person visits, particularly for those with limited mobility or living in remote areas.

Remote Monitoring Solutions

Heart failure, a prevalent and chronic cardiovascular condition, poses a significant healthcare challenge worldwide. The escalating prevalence of heart failure and the need for effective management have led to a surge in innovation within the healthcare industry. One key driver of growth in the Global Heart Failure Point of Care (POC) and Lab on a Chip (LOC) Devices Market is the integration of remote monitoring solutions.

In January 2024, Roche Diagnostics India achieved a significant milestone with the launch of its NT-proBNP test for point-of-care (POC) diagnostics. Designed for the cobas h 232 system, this test focuses on screening diabetes patients at high risk of cardiovascular diseases (CVD), including heart failure. By enabling faster and more accessible diagnostics, the test brings critical screening closer to clinics, transforming patient care. The NT-proBNP biomarker claim extension is specifically developed to enhance the early detection and management of heart failure, particularly in Type 2 diabetes (T2D) patients, improving clinical outcomes and supporting more personalized treatment strategies.

The incidence of heart failure is on the rise, primarily due to aging populations, unhealthy lifestyles, and an increase in risk factors such as obesity and diabetes. As more people are diagnosed with heart failure, the demand for efficient management solutions is increasing.

POC and LOC devices are at the forefront of diagnosing heart failure, allowing healthcare professionals to swiftly and accurately identify the condition. Early detection and intervention are critical in managing heart failure effectively and reducing hospitalization rates.

Remote monitoring solutions are pivotal in providing ongoing care for heart failure patients. These solutions extend beyond the initial diagnosis and allow healthcare providers to remotely monitor patients' vital signs, symptoms, and medication compliance.

Heart failure patients often experience readmissions to hospitals due to disease exacerbations. Remote monitoring allows healthcare providers to detect warning signs early, enabling timely interventions and reducing the need for costly and burdensome hospitalizations.

Remote monitoring empowers patients to take control of their health. With real-time data accessible through their devices, patients can actively engage in their treatment plans, making informed decisions, adhering to medications, and making lifestyle adjustments.

Remote monitoring eliminates the need for frequent in-person visits, making the management of heart failure more convenient for patients. This not only improves their quality of life but also enhances treatment adherence.

The rise of telemedicine, accelerated by the COVID-19 pandemic, has significantly contributed to the growth of remote monitoring solutions. POC and LOC devices can be seamlessly integrated into telemedicine platforms, facilitating remote consultations and monitoring for heart failure patients.

Patient-Centered Care

Heart failure, a widespread and debilitating cardiovascular condition, poses a formidable challenge to healthcare systems worldwide. The increasing prevalence of heart failure and a growing emphasis on improving patient outcomes have propelled innovations in the healthcare sector. One of the key drivers behind the growth of the Global Heart Failure Point of Care (POC) and Lab on a Chip (LOC) Devices Market is the adoption of a patient-centered care approach.

Heart failure is becoming increasingly prevalent due to aging populations, unhealthy lifestyles, and the rise of risk factors such as obesity and diabetes. As the number of heart failure patients continues to grow, there is a pressing need for innovative and patient-centric solutions.

Patient-centered care places the patient at the heart of healthcare decision-making. It emphasizes the importance of individual preferences, active patient involvement, and tailored healthcare experiences.

POC and LOC devices play a pivotal role in patient-centered care by putting the power of healthcare into the hands of patients. Patients can actively participate in their health management, leading to better adherence to treatment plans and lifestyle modifications.

In a patient-centered approach, patients are encouraged to actively engage in their treatment decisions. POC and LOC devices provide healthcare providers with accurate and timely data, enabling shared decision-making that is more in line with the patient's preferences and needs.

The ability to monitor vital signs and health parameters remotely reduces the need for frequent in-person visits and hospitalizations. This not only eases the patient's burden but also alleviates the strain on healthcare systems.

Patient-centered care, made possible through POC and LOC devices, improves the patient's overall quality of life. It allows for more personalized and less disruptive healthcare experiences, ultimately leading to greater well-being.

Global Awareness

Heart failure, a chronic and debilitating cardiovascular condition, has become a significant global health concern. The rising prevalence of heart failure, combined with an increasing awareness of the need for better diagnostics and management, is driving innovation in the healthcare sector. One of the pivotal factors contributing to the growth of the Global Heart Failure Point of Care (POC) and Lab on a Chip (LOC) Devices Market is the heightened global awareness surrounding heart failure.

Heart failure is becoming more prevalent, largely due to factors like aging populations, sedentary lifestyles, and the increasing incidence of risk factors such as obesity and diabetes. This upward trend in heart failure cases has created a pressing need for more effective diagnostics and management tools.

Over the past decade, there has been a significant increase in global awareness campaigns, initiatives, and educational programs aimed at informing the public about heart failure. Health organizations, nonprofits, and healthcare professionals have been instrumental in raising awareness about the condition's symptoms, risk factors, and the importance of early diagnosis and management.

Increased global awareness has led to earlier detection of heart failure in many cases. Patients are becoming more aware of the symptoms and risk factors, prompting them to seek medical attention sooner. This has led to better outcomes and reduced complications.

Healthcare professionals worldwide are also benefiting from heightened awareness. They are increasingly recognizing the importance of timely diagnosis and proactive management. POC and LOC devices have been instrumental in providing healthcare professionals with the tools needed for rapid and accurate diagnostics.

The global awareness surrounding heart failure has been further accelerated by the rapid expansion of telemedicine, particularly during the COVID-19 pandemic. POC and LOC devices can be seamlessly integrated into telemedicine platforms, facilitating remote consultations, and monitoring for heart failure patients, even in remote or underserved regions.

Heart failure is not limited by geographic boundaries. It affects people from diverse backgrounds and regions worldwide. The increased global awareness ensures that patients from various demographic and geographic segments have access to advanced healthcare solutions for heart failure diagnosis and management.

Regulatory authorities have recognized the importance of early diagnosis and proactive management in improving patient outcomes. This supportive regulatory environment encourages manufacturers to invest in research and development for POC and LOC devices.

Download Free Sample Report

Key Market Challenges

Accuracy and Reliability

POC and LOC devices need to be highly accurate and reliable, as errors can lead to misdiagnoses or improper management of heart failure. Ensuring consistent accuracy remains a significant challenge, especially for smaller and portable devices.

Regulatory Hurdles

The development and commercialization of POC and LOC devices require regulatory approvals and compliance with stringent quality standards. Achieving regulatory clearance is often a lengthy and complex process, delaying the market entry of innovative devices.

Cost Constraints

Developing POC and LOC devices with the necessary accuracy and features can be costly. Reducing the production costs while maintaining quality is a persistent challenge, especially for startups and smaller manufacturers.

Key Market Trends

Integration of Artificial Intelligence (AI)

Artificial intelligence is increasingly being incorporated into POC and LOC devices. AI can enhance diagnostic accuracy, personalize treatment plans, and provide predictive analytics to identify potential heart failure exacerbations before they occur.

Miniaturization and Portability

POC and LOC devices are becoming smaller and more portable, allowing for ease of use at home and in remote settings. This trend is making heart failure management more accessible and convenient for patients.

Multi-Parameter Monitoring

Emerging devices can monitor multiple parameters simultaneously, such as blood pressure, oxygen saturation, and various biomarkers. This comprehensive data collection enables a more holistic understanding of the patient's condition.

Segmental Insights

Technology Insights

The microfluidics sector secured the most substantial portion of revenue in 2024 and is poised to experience the swiftest CAGR in the projected period. There is a heightened concern about mortality and morbidity rates stemming from cardiovascular diseases (CVD), which has spurred a demand for prompt, portable, and cost-effective biosensing devices designed for cardiovascular event screening. Point-of-care (POC) biosensors play a pivotal role in the early detection of heart failure, eliminating the necessity for hospital visits and the associated laborious and expensive laboratory tests.

In recent years, the adoption of microfluidic biosensors has been on the rise, as they enable the integration and miniaturization of functional protocols typically carried out in centralized laboratories onto a portable chip. They offer multiple advantages, including reduced consumption of reagents and samples, as well as rapid turnaround times.

Consequently, over the past few years, there has been a significant uptick in the utilization of paper-based 3D microfluidics in POC applications due to their effectiveness in manipulating liquids at a high level. These factors have contributed to the dominant revenue share of microfluidic technology. Anticipated advancements in this technology are expected to propel the segment in the years ahead.

Download Free Sample Report

Regional Insights

Based on region, North America took the lead in the market, securing the largest portion of revenue. This was primarily driven by prominent market players in the United States, contributing significantly to the organic revenue growth in the global heart failure point-of-care (POC) and lab-on-a-chip (LOC) devices market. For instance, in December 2021, Quidel Corporation and Ortho Clinical Diagnostics Holdings plc entered into a business combination agreement. This agreement has led to enhanced patient access to a wide range of diagnostic products, including immunohematology, immunoassay, molecular diagnostics, clinical chemistry, donor screening, and point-of-care diagnostics.

Recent Developments

• In April 2024, Roche Diagnostics India introduced the NT-proBNP test on the cobas h 232 system to enhance early detection and intervention for diabetes patients at risk of cardiovascular disease (CVD). The test helps clinicians identify high-risk Type 2 diabetes (T2D) patients by measuring NT-proBNP levels, a key biomarker linked to heart failure and cardiovascular stress. This initiative supports the growing emphasis on personalized healthcare and early intervention in managing chronic diseases, enabling timely risk assessment and treatment adjustments. Roche’s launch reflects the increasing integration of biomarker-based diagnostics in improving patient outcomes for diabetes-related cardiovascular complications.
• In December 2022, Ultromics' EchoGo received FDA approval for its AI-powered technology designed for the accurate detection of heart failure with preserved ejection fraction (HFpEF). EchoGo leverages advanced artificial intelligence to enhance diagnostic precision, enabling earlier and more reliable identification of heart failure cases. This approval marks a significant step in integrating AI-driven solutions into cardiovascular diagnostics, improving patient outcomes through faster and more accurate assessments.
• In May 2022, BioMérieux acquired Specific Diagnostics, strengthening its position as a global leader in clinical microbiology. This acquisition introduced significant innovations to the market, enhancing BioMérieux’s capabilities in rapid pathogen detection and supporting its efforts in combating antimicrobial resistance. The integration of Specific Diagnostics’ advanced technologies further reinforces BioMérieux’s commitment to improving infectious disease diagnostics and advancing precision medicine worldwide.
• In December 2022, Ultromics' EchoGo received approval from the US Food and Drug Administration for their EchoGo device, an AI-driven technology that offers precise heart failure detection in cases with preserved ejection fraction. In May 2022, BioMérieux completed the acquisition of Specific Diagnostic, bolstering its global leadership in clinical microbiology. This strategic move brought significant innovation to the market and reinforced the company's efforts to combat antimicrobial resistance.
• Likewise, in October 2020, Abbott introduced implantable cardioverter defibrillator and cardiac resynchronization therapy defibrillator devices in the Indian market. These devices leverage smartphone connectivity and applications, introducing fresh opportunities for patient engagement and remote monitoring.

Key Market Players

• Abbott Laboratories Inc
• Siemens Healthineers AG
• Danaher Corp
• Instrumentation Laboratory Co
• F Hoffmann-La Roche AG
• bioMérieux S.A.
• Abaxis Inc
• Quidel Corp
• Jant Pharmacal Corp
• Trinity Biotech plc

Report Scope:

In this report, the Global Heart Failure POC And LOC Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Heart Failure POC And LOC Devices Market, By Test Type:

o   Proteomic testing

o   Metabolomic testing

o   Genomic testing

• Heart Failure POC And LOC Devices Market, By Technology:

o   Microfluidics

o   Array-based systems

o   Others

• Heart Failure POC And LOC Devices Market, By End Use:

o   Clinics

o   Hospitals

o   Home

o   Assisted living healthcare facilities

o   Laboratory

o   Others

• Heart Failure POC And LOC Devices Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  Germany

§  United Kingdom

§  France

§  Italy

§  Spain

o   Asia-Pacific

§  China

§  Japan

§  India

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

§  Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Heart Failure POC And LOC Devices Market.

Available Customizations:

Global Heart Failure POC And LOC Devices market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Heart Failure POC And LOC Devices Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com